Luke Miels will succeed Abbas Hussain as President, Global Pharmaceuticals, GSK

On 19 January, 2017, GlaxoSmithKline plc (LSE/NYSE: GSK) announced that Luke Miels has been appointed President, Global Pharmaceuticals, GSK. He will be responsible for a portfolio of medicines and vaccines with annual sales of more than ?15 billion and operations in over 100 markets. Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company. He has agreed with GSK that he will leave the company later this year.

Abbas joined GSK in 2008 and has held roles of increasing responsibility within the company’s pharmaceutical business. He is a member of GSK’s executive team and a board member of ViiV Healthcare.

Sir Andrew Witty, CEO, GSK commented, “In his time at GSK Abbas has proven himself to be one of the most talented and authentic leaders in the healthcare industry. I am personally grateful for his tremendous energy and support as a member of our executive team. I wish him well in his future and thank him for the significant contribution he has made to GSK and the lives of many patients around the world.”

Luke will report to Emma Walmsley, who is currently CEO Designate and will become CEO of GSK in April 2017. His start date will be announced in due course.

Luke is currently Executive Vice President (EVP) of AstraZeneca’s European business and was previously EVP, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.

Commenting on the appointment, Emma Walmsley said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.

“We are now entering a critical period of commercialisation for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline. Luke will bring a strong new voice to the decisions and choices we will have to make for our Pharmaceuticals business. I am delighted he has agreed to join GSK and look forward to welcoming him to the executive team.”

Over the course of his career, Luke has built highly effective strategic partnerships between R&D and the relevant commercial organisations to develop superior portfolio and product franchises at AstraZeneca, Roche and Sanofi-Aventis. He is known for being competitive and strongly focussing on the interests of patients.

Luke has significant international experience having worked and lived in the US, China, Singapore, the UK and continental Europe.

GSK enquiries:
UK Media ? enquiries:

?
David Mawdsley

?
+44 (0) 20 8047 5502

?
(London)

?

Simon Steel

Anna Carruth

+44 (0) 20 8047 5502

+44 (0) 20 8047 5502

(London)

(London)

US Media ? enquiries:

Sarah Alspach Sarah

Spencer

+1 202 715 1048

+1 215 751 3335

(Washington, DC)

(Philadelphia)

Analyst/Investor ? enquiries:

Sarah?Elton-Farr

Tom Curry

Gary Davies

James Dodwell

Jeff McLaughlin

+44 (0) 20 8047 5557

+ 1 215 751 5419

+44 (0) 20 8047 5503

+44 (0) 20 8047 2406

+1 215 751 7002

(London)

(Philadelphia)

(London)

(London)

(Philadelphia)